Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)

By sjmartinez • July 29, 2023

Ascierto PA, Agarwala SS, Warner AB, Ernstoff MS, Fox BA, Gajewski TF, Galon J, Garbe C, Gastman BR, Gershenwald JE, Kalinski P, Krogsgaard M, Leidner RS, Lo RS, Menzies AM, Michielin O, Poulikakos PI, Weber JS, Caracò C, Osman I, Puzanov I, Thurin M. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). J Transl Med. 2023 Jul 28;21(1):508. doi: 10.1186/s12967-023-04325-x. PMID: 37507765; PMCID: PMC10375730.

Tags: Adjuvant, Anti-CTLA-4, Anti-PD-1, biomarkers, BRAF inhibitor, Combination strategies, Dermatology, immunotherapy, MEK inhibitor, melanoma, neoadjuvant, Publications, Target therapy

Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis

Armstrong AW, Ameen A, Ferrucci S, Pereyra-Rodríguez JJ, Cork MJ, Rubin C, Jarell A, Narcisi A, Becherel PA, Beecker J, Festini T, Vittrup I, Vinther[...]

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review

Armstrong AW, Strober BE, Liu CM, Cather JC, Merola JF, Lebwohl MG. Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a[...]

Microporous Annealed Particle Wound Matrix for Post-Mohs Defects: A Randomized Controlled Multicenter First-In-Human Study

Hau JT, Martin SJ, Roosa CA, Deshayes S, Hanke CW. Microporous Annealed Particle Wound Matrix for Post-Mohs Defects: A Randomized Controlled Multicenter First-In-Human Study. Dermatol[...]